Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: Aspirin and Omega-3 in Diabetes
NCT00135226Phase 4Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Mar 2005
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aspirin and omega-3-acid ethyl ester in cardiovascular disease (CVD), sponsored by University of Oxford. Started Mar 2005; status: active, not recruiting.
02
Drugs
aspirinomega-3-acid ethyl ester
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00135226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135226.